Skip to main content
Delfa

← All assets

Choline alfoscerate

5 trials in this asset. Source: ClinicalTrials.gov, as of July 21, 2026.

Trials

5

Ongoing

0

Recruiting

0

Completed

2

Sites

7

Countries

2

Endpoints

27

Composite endpoints

0

Distinct sites and countries across this asset's trials. A site running several of its trials counts once, matching the map. All 27 linked ClinicalTrials.gov endpoints are classified into the categories below. Trial and endpoint linkage does not by itself establish treatment attribution for every endpoint.

Development

Where the program stands

Trials by phase

Phase 2
1
Phase 4
4

Trials by status

Completed
2
Unknown
3

Evidence coverage

What this asset has been measured on

Endpoints grouped into outcome categories, ranked by how often they are measured across this asset's trials.

Global cognition
15
Other (unclassified)
4
Executive function / language
3
Memory
1
Function / daily living
1
Behavior / neuropsychiatric
1
Caregiver / quality of life
1
Safety / tolerability / PK
1

Most-measured metrics

Top 20 metrics across this asset's endpoints

Normalized metric codes are available for 14 of 27 classified ClinicalTrials.gov endpoints for this asset; the ranking below covers that coded subset.

ADAS-CogCognition

7

Mini-Mental State Examination (MMSE)Cognition

3

Montreal Cognitive Assessment (MoCA)Cognition

2

Clinical Dementia Rating-Sum of Boxes (CDR-SB)Cognition

2

Trials

Trials for this asset

Every trial for this asset, with the same search, filters, and sort as the Trials tab.

5 of 5

Alzheimer’s disease and related dementias trials
Asset / Disease areaKey I/E criterionEvidence
COALAEfficacy and Safety of ChOline ALfoscerate in Patient With Mild to Moderate Alzheimer's Disease

Choline alfoscerate

Alzheimer’s disease

MMSE ≤26Ph 4Unknown4Jun 2025-
NCT05050604A Clinical Trial to Evaluate the Efficacy and Safety of Choline Alfoscerate in Vascular Cognitive Impairment Patients

Choline alfoscerate

Vascular cognitive impairment / dementia

Age ≥50Ph 4Unknown1Nov 2024-
GLITTERThe Efficacy of Gliatiline® on Post-stroke Patients With Vascular Cognitive Impairment no Dementia

Choline alfoscerate

Vascular cognitive impairment / dementia

Age 25-84Ph 4Completed1Mar 20131
CONIVADCholine Alphoscerate-Nimodipine in Vascular Cognitive Impairment

Choline alfoscerate

Vascular cognitive impairment / dementia

Age ≥65Ph 2Completed1Jul 201913
NCT02648906A Clinical Trial for an Evaluation of Choline Alfoscerate and Donepezil for Cognitive Improvements of Patients With Cerebrovascular Injury in Alzheimer Patients

Choline alfoscerate

Alzheimer’s disease

MMSE 12-24Ph 4Unknown1Nov 2018-

Showing 1-5 of 5 trials